Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: October 14, 2025
Reporting Period: Event date October 14, 2025; Press release issued October 15, 2025.
Context: The Company is an emerging growth company listed on the Nasdaq Capital Market. This filing addresses the resolution of compliance issues regarding Nasdaq listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance status.
Material Changes
- Regulatory Status: The Nasdaq Hearings Panel found the Company in compliance with Listing Rule 5550(a)(2) (Minimum Bid Price Rule) and 5550(b)(1) (Minimum Stockholders' Equity Rule).
- Monitoring Requirement: The Company is subject to a mandatory panel monitor for a period of one year.
- Delisting Risk: If the Company fails to comply with the Minimum Stockholders' Equity Rule during the one-year monitoring period, it will not be permitted additional time to regain compliance. However, the Company retains the right to request a new hearing prior to delisting.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on October 15, 2025, confirming it has regained compliance with Nasdaq listing requirements.
Risks and Contingencies:
- Compliance Risk: The primary risk is failure to maintain Minimum Stockholders' Equity during the one-year monitoring period, which could lead to immediate delisting proceedings without a grace period.
- Operational Impact: No unusual items or operational changes were disclosed in this filing.
Investor Verification Checklist
- Verify the current stock price to ensure continued compliance with the Minimum Bid Price Rule.
- Review the Company's most recent 10-Q or 10-K to confirm the current level of Stockholders' Equity.
- Monitor future 8-K filings for any notices of non-compliance during the one-year monitoring period.
- Confirm the terms of the press release attached as Exhibit 99.1 for any additional details on the compliance path.